Rising Cases Of Premature Births Driving Growth In The Market Due To Increasing Risk In Preterm Infants: A Key Driver Powering Necrotizing Enterocolitis Market Growth In 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Current Necrotizing Enterocolitis Market Size and Its Estimated Growth Rate?
In recent times, there has been substantial growth in the market size of necrotizing enterocolitis. A rise from $4.83 billion in 2024 to $5.16 billion in 2025 is projected, with a compound annual growth rate (CAGR) of 6.8%. The notable growth during the historical period can be credited to the growing incidence of necrotizing enterocolitis, rise in population numbers, elevated per capita income, enhanced government funding, and an increase in premature birth cases.

The market size for necrotizing enterocolitis is anticipated to witness vigorous growth over the TH*Coming years, expected to amass a value of $6.62 billion in 2029 with a 6.4% compound annual growth rate (CAGR). The projected growth in this period can be credited to a surge in TH*Care costs, the occurrence and prevalence of ulcerative colitis (UC), a rise in gastrointestinal diseases, an uptick in the elderly and obese demographics, and the expanding elder population. The notable trends expected during this forecast period encompass progress in biomarker research for initial NEC detection, breakthroughs in non-invasive testing procedures, the uptake of sophisticated monitoring systems, developments in surgical practices, and the evolution of targeted therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

How Are Emerging Segments Shaping the Necrotizing Enterocolitis Market Landscape?
The necrotizing enterocolitis market covered in this report is segmented -

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments
2) By Diagnosis: Laboratory Tests, Imaging Techniques
3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)
4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:
1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN
2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques
3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates
4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC
5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques
6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Which Growth Factors Are Influencing Necrotizing Enterocolitis Market Expansion?
The growth of the necrotizing enterocolitis market is anticipated to be fueled by the rising instances of premature births. Premature births, often referred to as preterm births, are when a child is delivered before the 37th week of gestation, as opposed to the standard 40-week term of pregnancy. The escalation in premature births can be attributed to maternal health issues like hypertension, diabetes, and infections, which amplify the chances of preterm labor. Furthermore, lifestyle choices like smoking, drug consumption, and inadequate nutrition can lead to a greater probability of premature births. An increase in premature births results in a higher number of necrotizing enterocolitis (NEC) cases, as the underdeveloped gastrointestinal systems of premature babies heighten their vulnerability to inflammation and infection. To illustrate, data from the Centers for Disease Control and Prevention, a governmental agency in the U.S, from January 2024, shows that premature births represent 8.67% of all births annually in the country. As a result, the surge in premature births is propelling the expansion of the necrotizing enterocolitis market.

Who Are the Dominant Players Across Different Necrotizing Enterocolitis Market Segments?
Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

What Are the Latest Developing Trends in the Necrotizing Enterocolitis Market?
Leading corporations in the necrotizing enterocolitis industry are concentrating their efforts on the creation of novel product solutions, such as cell-free sterile biologic remedies, to cater to the profound unaddressed need for effective treatment modalities and enhance outcomes for prematurely born infants. A cell-free sterile biologic treatment is a refined, sterile fluid comprised of bioactive molecules like proteins, growth stimulants, and cytokines obtained from cultured cells, but devoid of any living cells. These are tailored to facilitate healing and decrease inflammation. For illustration, Noveome Biotherapeutics, Inc., an American biopharmaceutical enterprise, was enabled to advance with its Phase 1-2 clinical trial for ST266, a pioneering biologic targeting the treatment of necrotizing enterocolitis (NEC) in premature infants, following a notification from the U.S. Food and Drug Administration (FDA) in December 2023. This serves as a notable landmark, given that ST266 is projected to be the foremost major therapeutic progress for NEC in more than three decades, addressing a crucial TH*Care necessity considering the high morbidity and mortality rates resulting from the disease among susceptible groups.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Geographic Regions Are Expected to Dominate the Necrotizing Enterocolitis Market in the Coming Years?
North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Necrotizing Enterocolitis Market?
2. What is the CAGR expected in the Necrotizing Enterocolitis Market?
3. What Are the Key Innovations Transforming the Necrotizing Enterocolitis Industry?
4. Which Region Is Leading the Necrotizing Enterocolitis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.